This platform enables the co-delivery of tumor-associated antigen (TAA) and N6-methyladenosine demethylase (m6A) inhibitors (i.e., fat mass and obesity-associated gene (FTO) inhibitors) into tumor-infiltrating dendritic cells (TIDCs) to more effectively suppress the metastasis and recurrence of HCC following thermal ablation. The gene discussed is FTO; the disease is hepatocellular carcinoma.